Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1") |
||
| Line 35: | Line 35: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34818478/ PubMed] NCT03401788 | + | # '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34818478/ PubMed] https://clinicaltrials.gov/ct2/show/NCT03401788 |
[[Category:Renal cell carcinoma regimens]] | [[Category:Renal cell carcinoma regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Renal cell carcinomas]] | [[Category:Renal cell carcinomas]] | ||
Revision as of 13:02, 6 June 2023
Section editor transclusions Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Belzutifan monotherapy
Regimen
| Study | Dates of enrollment | Evidence | |
|---|---|---|---|
Jonasch et al. 2021 (MK-6482-004)
|
2018-05-31 to 2019-03-29 | Phase 2 (RT) |
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article PubMed https://clinicaltrials.gov/ct2/show/NCT03401788